Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Ann Allergy Asthma Immunol ; 83(4): 335-40, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10541426

ABSTRACT

BACKGROUND: Several longitudinal studies report that allergic sensitization increases with age from childhood to adulthood. OBJECTIVE: To evaluate whether an age-dependent tendency to become sensitized to new classes of allergens is present in atopic children, we studied retrospectively the changes in allergic sensitization in 165 asthmatic patients, monosensitized (ie, sensitized to only one class of allergens) in the first survey. METHODS: All the children (18 months to 8 years at enrollment), attended our outpatient clinics twice, at time intervals ranging from 2 to 10 years. On each visit, sensitization to house dust mites, pollens, animal danders, and molds was determined by skin prick test. RESULTS: We found that 43.6% (n = 72) of the patients became polysensitized on the second survey. According to age on first survey, the patients were further divided into two age groups: (1) group 1 = 18 months to < 5 years old (n = 98) and (2) group 2 = 5 to 8 years (n = 67). The transition from monosensitization to polysensitization observed in the entire population was present in both groups: 47 (47.9%) of the 98 children in group 1 and 25 (37.3%) of the 67 children in group 2 showed to be sensitized to more classes of allergens, as compared with first survey. Both in the whole population and in the two age subgroups, the changes in the frequency of monosensitization between the two evaluations were time-dependent (P < .05, each Chi(2)). Finally, to investigate whether monosensitization to a specific class of allergens could favor the development of polysensitization, we evaluated the frequency of polysensitization in the second survey in patients originally monosensitized to house dust mites or to pollens. We found that of the 130 patients originally monosensitized to house dust mites, 59 became polysensitized (45.4%), while of the 28 patients originally monosensitized to pollens, 9 became polysensitized (32.1%) (P > . 1). Similar results were obtained when patients were divided into age groups. CONCLUSION: These data demonstrate that (1) monosensitized children are likely to become polysensitized and (2) house dust mite sensitization and, at a lower degree, pollen sensitization, apparently seem to play a "triggering" role in the development of polysensitization, since a high proportion of children originally monosensitized to house dust mites or to pollens became polysensitized.


Subject(s)
Allergens/adverse effects , Asthma/immunology , Hypersensitivity, Immediate/immunology , Adolescent , Age Factors , Allergens/classification , Animals , Animals, Domestic/immunology , Asthma/etiology , Child , Child, Preschool , Disease Susceptibility , Fungi/immunology , Humans , Immune System/growth & development , Immunization , Mites/immunology , Pollen/immunology , Retrospective Studies , Skin Tests
2.
Allergy ; 52(7): 752-4, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9265991

ABSTRACT

Cetirizine, an antihistamine widely used in the treatment of allergic rhinoconjunctivitis, also has antiallergic activity. The present study aimed to evaluate cetirizine as a treatment for children with allergic cough due to pollen allergy. This was a parallel-group, double-blind, placebo-controlled, randomized study. Twenty children with pollinosis were enrolled: they were subdivided into two groups receiving a 1-month treatment during the pollen season. The following variables were monitored: 1) clinical symptoms and respiratory data (spirometry and PEF) evaluated at baseline and at the end of the study by allergists and by a daily diary card, and 2) pollen count. This study shows that cetirizine treatment reduces cough intensity (P < 0.05) and frequency (P < 0.01). In conclusion, cetirizine does clinically improve cough due to pollen allergy.


Subject(s)
Anti-Allergic Agents/therapeutic use , Cetirizine/therapeutic use , Respiratory Hypersensitivity/drug therapy , Adolescent , Anti-Allergic Agents/administration & dosage , Cetirizine/administration & dosage , Child , Cough/diagnosis , Cough/immunology , Double-Blind Method , Female , Humans , Male , Peak Expiratory Flow Rate , Pollen/immunology , Spirometry
3.
Ital J Gastroenterol Hepatol ; 29(2): 155-61, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9646197

ABSTRACT

BACKGROUND: In children with Wilson's disease, no clinical or laboratory data are specific for diagnosis as in adult age. AIM: Clinical aspects and parameters of copper metabolism in a large series of pediatric cases are evaluated to establish certain criteria for diagnosis and for correct treatment, even in difficult cases. METHODS: In 44 children with Wilson's disease, clinical aspects, histological features, laboratory parameters and data of copper metabolism have been studied. Forty patients, treated with penicillamine, were followed up (median 77 months). RESULTS: The 44 cases were classified as: asymptomatic forms (nine cases, six of them siblings of affected subjects), chronic hepatitis (23 cases), hepatocerebral manifestations (four cases), decompensated cirrhosis (six cases), fulminant hepatic failure with hemolytic anemia (two cases). Ceruloplasmin levels were abnormal in 37 out of 43 tested cases, but normal in six (14%) who showed high basal and after penicillamine load urine copper excretion and increased hepatic copper content. Urine copper concentration was pathological in 35 out of 42 tested cases (83%), but normal in seven patients under six years. Hepatic copper levels were very high in all the 20 tested patients. Under treatment, 27 children had favourable outcome. One patient showed no evolution of disease, seven patients worsened because of non-compliance to the therapy (one underwent successful liver transplantation) or severe side effects. Five patients with failure died. CONCLUSIONS: Wilson's disease in children may present with a broad clinical spectrum, but the liver involvement is by far the most prevalent. The early diagnosis, based on clinical suspicion and results of copper metabolism investigation (including hepatic copper content evaluation in difficult cases) and appropriate treatment can prevent the progression of the disease.


Subject(s)
Hepatolenticular Degeneration/diagnosis , Adolescent , Chelating Agents/therapeutic use , Child , Child, Preschool , Copper/metabolism , Female , Hepatolenticular Degeneration/drug therapy , Hepatolenticular Degeneration/pathology , Hepatolenticular Degeneration/physiopathology , Humans , Male , Penicillamine/therapeutic use
4.
Int Arch Allergy Immunol ; 109(3): 272-6, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8620097

ABSTRACT

It has been recently demonstrated that individuals who suffer from mite allergy present mucosal inflammation even when asymptomatic. This situation is characterized by infiltration of inflammatory cells (eosinophils and neutrophils) and by ICAM-I expression on epithelial cells. It has been called 'minimal persistent inflammation' (MPI) for its relationship with natural exposure to allergen, which is continuous in the case of mite allergy. ICAM-I (or CD54) expression on epithelial cells is relevant for several reasons: (a) healthy individuals and patients with pollen allergy out of the pollen season do not express this molecule; (b) ICAM-I is the natural ligand of LFA-1 (an integrin expressed on granulocytes), and (c) ICAM-I is also receptor for rhinoviruses. It is well known that viral infections precede asthmatic attacks; consequently, this correlation is more frequent in cases of mite allergy. Cetirizine is an antiallergic drug that can reduce both inflammatory infiltrate and ICAM-I expression induced by allergen-specific conjunctival challenge. The aim of this study was to evaluate the effect of cetirizine on MPI in 20 children (5-14 years old) with mite allergy. All the children suffered from mild asthma and 9 also had rhinitis (they had been asymptomatic, and thus not treated, for 2 months). The study was double-blind, placebo controlled and randomized and children took Cetirizine or placebo for 15 days. At the beginning and end of the study, nasal scrapings were performed to evaluate inflammatory cell infiltration (eosinophils and neutrophils) and ICAM-I expression on epithelial cells. Cetirizine-treated children showed a significant reduction (or even total absence) of ICAM-I expression on epithelial cells (p less than 0.002) and a reduction trend in inflammatory cell counts compared with placebo. In conclusion, Cetirizine might be envisaged as fruitful for the prolonged treatment of allergic children, including during clinical latency, to prevent possible relapse or rhinovirus infections.


Subject(s)
Asthma/drug therapy , Asthma/pathology , Cetirizine/pharmacology , Glycoproteins/immunology , Intercellular Adhesion Molecule-1/drug effects , Mites/immunology , Nasal Mucosa/drug effects , Nasal Mucosa/pathology , Adolescent , Allergens/immunology , Animals , Antigens, Dermatophagoides , Asthma/etiology , Child , Child, Preschool , Double-Blind Method , Epithelium/drug effects , Epithelium/pathology , Humans
6.
Clin Exp Rheumatol ; 11(2): 203-8, 1993.
Article in English | MEDLINE | ID: mdl-8508564

ABSTRACT

In this study we have investigated the efficacy and safety of cyclosporin A (CyA) in a group of pediatric patients with juvenile chronic arthritis (JCA, 9 cases) and polymyositis-dermatomyositis (PM-DM, 3 cases). Of the 9 JCA patients, 7 had the systemic and 2 the polyarticular form of the disease. All of the patients received CyA after the failure of corticosteroids and/or cytotoxic drugs. CyA was administered for 9 to 48 months at a mean dose of 5 mg/kg/day. Ten patients received corticosteroids with CyA. The results of CyA treatment were satisfactory overall, both in the PM-DM patients and in the JCA patients, as assessed by clinical and laboratory evaluation. CyA-related side effects included alopecia, hypertension, hypertrichosis, tremors, and hirsutism. One JCA patient developed polyserositis with hypoproteinemia of unknown origin while receiving CyA. CyA blood levels did not correlate with clinical efficacy and/or side effects. This study suggests that CyA represents a promising agent for the treatment of JCA and childhood PM-DM.


Subject(s)
Arthritis, Juvenile/drug therapy , Cyclosporine/therapeutic use , Dermatomyositis/drug therapy , Polymyositis/drug therapy , Adolescent , Child , Cyclosporine/adverse effects , Cyclosporine/standards , Dose-Response Relationship, Drug , Female , Humans , Male , Time Factors
8.
Minerva Pediatr ; 43(10): 621-30, 1991 Oct.
Article in Italian | MEDLINE | ID: mdl-1758383

ABSTRACT

Juvenile dermatomyositis (DMI) is a rare illness of multisystem inflammatory disease of unknown etiology. It is usually considered as a part of the spectrum of polymyositis/dermatomyositis (PM/DM), and is distinguished from the adult form in having a number of different clinical features as well as distinctive pathologic findings. Although the clinical findings and course of the disease, laboratory evaluation and therapy have been reviewed, many of these studies are old and may not accurately reflect the current status of the disease as it is now defined and treated. Generally it is first diagnosed by the appearance of typical signs in both the skin and muscles. The clinical picture shows early signs of heterogeneity and is confirmed by these latter developments. Its classification falls into three groups: acute single cycle, chronic polycycle and continued chronic; this sickness invariably evolves into one or another of these three. Our current work involves 15 cases of DMI; 8 have acute monocycle, 4 chronic polycycle and 3 continued chronic. This illustrates the clinical and biological heterogenousness of this illness which in itself presents extreme difficulties when considering possible treatment. From our experience, high dose of corticosteroida intraveins have had the best result. Where cases have been acute at the beginning of the sickness and where there has been complications, particularly those of a bronco-pulmonary nature (we treated 3 such cases) it has proven to be beneficial to use corticosteroid together with the immunosuppresant: ciclofosfamide. The use of ciclosporina in one case who had resisted other forms of therapy has appeared to be effective, though this has yet to be verified.


Subject(s)
Dermatomyositis , Acute Disease , Adolescent , Adrenal Cortex Hormones/therapeutic use , Biopsy , Child , Child, Preschool , Chronic Disease , Cyclophosphamide/therapeutic use , Cyclosporine/therapeutic use , Dermatomyositis/diagnosis , Dermatomyositis/drug therapy , Drug Therapy, Combination , Female , Humans , Male
9.
Clin Exp Rheumatol ; 9(4): 425-30, 1991.
Article in English | MEDLINE | ID: mdl-1934695

ABSTRACT

We review 30 cases of pediatric systemic lupus erythematosus followed over an 8-year period at our institution. The female to male ratio was 3.3:1; the age at diagnosis ranged between 3.5 and 16 years. On first admission, renal involvement was detected in the majority of the patients, as assessed by laboratory findings and/or clinical manifestations. Other frequently observed symptoms were fever, skin rashes, arthralgias and/or arthritis and serositis. All of the patients were treated with corticosteroids and most of them also received immunosuppressive drugs in order to control disease activity. Two patients were lost to the follow-up, five died and only one of the 23 evaluable patients is off therapy after a median follow-up of 5 years. This study confirms that pediatric systemic lupus erythematosus is a very aggressive disease.


Subject(s)
Lupus Erythematosus, Systemic/pathology , Adolescent , Adrenal Cortex Hormones/therapeutic use , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Italy/epidemiology , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Male
16.
Pediatr Med Chir ; 8(1): 85-8, 1986.
Article in Italian | MEDLINE | ID: mdl-3725618

ABSTRACT

The authors shortly report on the frequency and the peculiar clinical picture in the paediatric age. The usefulness of the pharmacological control (Ranitidine i.v. 50 mg thrice for 3 days) of acute haemorrhagic compliances is discussed in reference to the patient. The same drug was continued per os for two month at a dosage of 150 mg twice daily followed by 150 once daily for 8 months; during this period no relapses were observed and an endoscopic control did show the anatomical recovery of the ulcer. The authors underline also the good compliance and the absence of side effects of the drug employed.


Subject(s)
Duodenal Ulcer/drug therapy , Peptic Ulcer Hemorrhage/drug therapy , Ranitidine/therapeutic use , Child , Drug Administration Schedule , Duodenal Ulcer/diagnosis , Duodenoscopy , Female , Humans
18.
J Urol (Paris) ; 89(5): 331-40, 1983.
Article in French | MEDLINE | ID: mdl-6631039

ABSTRACT

The authors report the results of percutaneous dilatation of renal artery stenoses, performed on 8 occasions in 7 patients. One patient had bilateral stenoses which were operated at two separate occasions. The authors had no complications and they confirm the stability of the results with a follow-up of up to 2 years. In the 4 cases with an isolated unilateral renal artery stenosis, dilatation of the artery led to normalization of the blood pressure within hours of the operation. When there was another cause for hypertension apart from the renal artery stenosis, the dilatation did not cause the blood pressure to return to normal, although the anatomical result was confirmed on arteriography. The authors then review the literature and compare the complications of surgery for renal artery stenoses with those occurring during or after percutaneous dilatation of the renal artery lumen. Because of the quality of the results, the complication rate and the good results obtained with percutaneous dilatation in the literature, the authors conclude that percutaneous dilatation of the renal artery lumen is the treatment of choice for these stenoses. The indication for this operation can be extended, as its aim is not only reduction of hypertension, but also to improve renal function and to avoid the risk of thrombosis on a very narrow stenosis. In this way, the indications for this operation extend to include a population which, up until now, has been excluded from surgery, such as elderly patients, patients with coronary disease, or with renal failure.


Subject(s)
Catheterization/methods , Renal Artery Obstruction/therapy , Aged , Dilatation/methods , Female , Humans , Male , Middle Aged , Postoperative Complications , Radiography , Renal Artery Obstruction/diagnostic imaging , Renal Artery Obstruction/surgery
19.
J Urol (Paris) ; 89(3): 187-190, 1983.
Article in French | MEDLINE | ID: mdl-6875299

ABSTRACT

The authors report a preliminary study of 12 cases of carcinoma of the prostate confined to the prostate (T1, T2, T3, NO, MO) treated by pelvic lymphadenectomy and the implantation of grains of I 125 in the prostatic tissue. Irradiation continued for six months, providing most dose of 100 Gy in the prostate. Interstitial irradiation caused not only the destruction of tumour cells but also "radiation prostate" lesions with vascular obliteration which itself caused sufficient impairment of the vitality of the prostatic tissue for any residual tumour to disappear with a frequency which increased with the time elapsing between the follow up prostatic biopsy and the implantation of radioactive iodine. Experience remains limited but the initial figures given here suggest the validity of continuing along these lines.


Subject(s)
Adenocarcinoma/radiotherapy , Brachytherapy , Iodine Radioisotopes/therapeutic use , Prostatic Neoplasms/radiotherapy , Adenocarcinoma/pathology , Follow-Up Studies , Humans , Male , Prostate/pathology , Prostatic Neoplasms/pathology
20.
J Radiol ; 63(6-7): 445-8, 1982.
Article in French | MEDLINE | ID: mdl-7131415

ABSTRACT

Two new indications for the application of endo-urological techniques are reported. One case involved recanalization of stenosis at the ureterovesical junction, while in the other case a double J ureteral endoprosthesis was extracted by the transnephropyelostomy percutaneous route.


Subject(s)
Urinary Catheterization/methods , Urinary Tract/surgery , Adult , Female , Humans , Kidney/surgery , Male , Middle Aged , Ureter/surgery , Urinary Catheterization/instrumentation
SELECTION OF CITATIONS
SEARCH DETAIL
...